Huntsville, Ala. —HudsonAlpha associate company Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology platform for drug development (POZTM) based upon polyoxazoline; announced today that the Dr. Randall Moreadith, President and CEO, will deliver an invited lecture on August 22nd at the annual American Chemical Society Meeting in Philadelphia celebrating the 50th anniversary of the first synthesis of polyoxazoline polymers.
“I am delighted to be invited to speak on this occasion celebrating the 50th anniversary of the synthesis of the first polymer of polyoxazoline. That groundbreaking achievement set the stage for development of POZ, Serina’s robust and versatile proprietary drug delivery platform based on the combination of polyoxazoline and the company’s patented linker technology.” said Dr. Moreadith. “Serina Therapeutics has long been a pioneer in the field of polymer therapeutics and established itself as a leader with the initiation of the clinical development of SER-214, the first POZ-based therapeutic, earlier this year.”
SER-214, a once-per-week subcutaneous administration of rotigotine delivered in a standard insulin syringe, is currently being studied in a Phase I program in patients suffering from Parkinson’s disease. “SER-214 is designed to deliver therapeutic levels of rotigotine over the entire dosing period thereby providing continuous dopaminergic tone and preventing the phasic peak and trough of many oral dopamine-like drugs that lead to the disabling dyskinesias eventually experienced by all patients.” said Dr. Moreadith. “We believe that SER-214 will not only become an important therapeutic in the treatment of Parkinson’s disease allowing patients to enjoy a better quality of life for a longer period, but will also demonstrate the power of the POZ platform in addressing unmet medical need through customized drug delivery.”
In addition to advancing its pipeline programs in pain, oncology, refractory seizures and inflammatory diseases, Serina is currently collaborating with leading pharmaceutical companies to further unlock the promise of the POZ platform and actively seeking new partnerships.
About Serina: Serina Therapeutics is a privately held pharmaceutical company located at the HudsonAlpha Institute for Biotechnology in Huntsville, AL that has developed novel polymer therapeutics based on its proprietary polyoxazoline (POZTM) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled thirteen approved polyethylene glycol (PEG) products
About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological challenges. Opened in 2008, its mission is four-fold: sparking scientific discoveries that can impact human health and well-being; bringing genomic medicine into clinical care; fostering life sciences entrepreneurship and business growth; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus encourage collaborations that produce advances in medicine and agriculture. Under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education, and includes more than 30 diverse biotech companies on campus. To learn more about HudsonAlpha, visit: http://hudsonalpha.org/.
HudsonAlpha Media Contact: